I have beeen watching from the sidelines for about 18months now. The data delivered so far is very promising and there are positive noises coming about the data fro Phase 2 for November. If it is positive there must be decisions being made on how to profit from the expense incurred so far. Have manufactured under licence, manufacture in-house. Who and where will it be manufactured, what costs will be borne by Immutep.
My hope and expectation is that it is manufactured/distributed under licence by big pharma. This will speed up the revenue streams and impact on capital raising needs.
Alternatively given the portfolio of potential scoring shots be bought out by big Pharma.
Thanks for the comments.
I have beeen watching from the sidelines for about 18months now....
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |